Endo International Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Endo International.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth	23.6%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

Recent updates

Endo creditors looking at putting company up for sale through bankruptcy - Bloomberg

Aug 16

Endo: Appellate Court Denies Request To Postpone Damages Trial Might Be End O' The Road

Jul 15

Endo International: Bankruptcy Seems Like The Only Practical Option

Jun 30

Endo International wins FDA approval for Micafungin new formulation

Jun 17

Endo International plc 2021 Q1 - Results - Earnings Call Presentation

May 07

Radius Health partners with Endo unit for abaloparatide in Canada

Jan 05

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Endo International has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

OTCPK:ENDP.Q - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2023	2,012	-2,448	341	435	N/A
9/30/2023	2,070	-252	334	430	N/A
6/30/2023	2,160	-942	285	391	N/A
3/31/2023	2,182	-2,847	21	130	N/A
12/31/2022	2,319	-2,910	166	269	N/A
9/30/2022	2,552	-3,221	11	110	N/A
6/30/2022	2,783	-2,552	-9	80	N/A
3/31/2022	2,928	-681	277	369	N/A
12/31/2021	2,993	-569	326	411	N/A
9/30/2021	2,964	129	484	569	N/A
6/30/2021	2,827	109	345	429	N/A
3/31/2021	2,801	137	506	579	N/A
12/31/2020	2,903	247	327	402	N/A
9/30/2020	2,908	-102	195	268	N/A
6/30/2020	3,002	-75	299	378	N/A
3/31/2020	3,014	-190	180	251	N/A
12/31/2019	2,914	-361	30	98	N/A
9/30/2019	2,936	-418	108	190	N/A
6/30/2019	2,952	-522	63	135	N/A
3/31/2019	2,967	-477	47	128	N/A
12/31/2018	2,947	-962	177	267	N/A
9/30/2018	2,929	-968	238	329	N/A
6/30/2018	2,971	-921	324	434	N/A
3/31/2018	3,132	-1,565	311	435	N/A
12/31/2017	3,469	-1,233	428	554	N/A
9/30/2017	3,942	-4,294	N/A	507	N/A
6/30/2017	4,039	-4,386	N/A	309	N/A
3/31/2017	4,084	-3,300	N/A	742	N/A
12/31/2016	4,010	-3,224	N/A	528	N/A
9/30/2016	3,842	553	N/A	683	N/A
6/30/2016	3,704	-59	N/A	698	N/A
3/31/2016	3,518	-539	N/A	106	N/A
12/31/2015	3,269	-300	N/A	119	N/A
9/30/2015	2,858	-725	N/A	-75	N/A
6/30/2015	2,766	128	N/A	310	N/A
3/31/2015	2,624	260	N/A	492	N/A
12/31/2014	2,381	58	N/A	338	N/A
9/30/2014	2,303	-643	N/A	277	N/A
6/30/2014	2,310	-637	N/A	141	N/A
3/31/2014	2,429	-650	N/A	124	N/A
12/31/2013	2,125	189	N/A	299	N/A
9/30/2013	2,621	-628	N/A	711	N/A
6/30/2013	2,711	-629	N/A	683	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if ENDP.Q's forecast earnings growth is above the savings rate (2.4%).

Earnings vs Market: Insufficient data to determine if ENDP.Q's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if ENDP.Q's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if ENDP.Q's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if ENDP.Q's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if ENDP.Q's Return on Equity is forecast to be high in 3 years time

Endo International Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Price target decreased to US$2.63

Price target decreased to US$6.17

Price target decreased to US$6.57

Consensus forecasts updated

Price target raised to US$7.45

Price target raised to US$6.91

Recent updates

Fourth Amended Reorganization Plan Filed by Endo International plc

Endo International plc to Report Q3, 2023 Results on Nov 06, 2023

Endo International plc, Annual General Meeting, Sep 07, 2023

Endo International plc Launches First Generic Version of Noxafil® (posaconazole) Injection

Endo International plc Announces First Patient Enrolled in Registry of Dupuytren's Contracture

Endo International plc Launches PREVDUO (Neostigmine Mylsulfate and Glycopyrrolate Injection), the First and Only FDA-Approved Neostigmine-Glycopyrrolate Combination Pre-Filled Syringe

Two Affiliate Companies Joined Endo International plc Bankruptcy

Endo International plc Announces Asset Impairment Charges for Three Months Ended March 31, 2023

Endo International plc and SMSNA Launches App to Provide Peyronie's Disease Self-Assessment Tool

Nasdaq to Delist Common Stock of Endo International

Endo International Provides Delisting Update

Endo International plc(NasdaqGS:ENDP) dropped from NASDAQ Biotechnology Index

Endo International plc(NasdaqGS:ENDP) dropped from S&P TMI Index

Endo International plc Filed for Bankruptcy

Endo International plc Filed for Bankruptcy

Endo creditors looking at putting company up for sale through bankruptcy - Bloomberg

Second quarter 2022 earnings released: US$8.00 loss per share (vs US$0.044 loss in 2Q 2021)

Endo International sees 23% rise on 3x higher than normal volume

Endo outperforms defying bankruptcy fears and generic entry

Endo weighs bankruptcy filing without opioid settlement - WSJ

Endo International Receives Non-Compliance Notice from Nasdaq

Endo International cools off, giving back some of its 85% Tuesday gain

Endo International plc(NasdaqGS:ENDP) dropped from S&P Pharmaceuticals Select Industry Index

Endo: Stick A Fork In It

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Endo Aesthetics to Introduce New Clinical Study of Qwo® (collagenase clostridium histolyticum-aaes) at the Annual SCALE Meeting

Price target decreased to US$2.63

Endo International plc to Report Q1, 2022 Results on May 05, 2022

Edesa Biotech, Inc. Appoints Jennifer M. Chao to its Board of Directors

Endo Begins Shipment of Premixed Ephedrine Sulfate Injection in Ready-To-Use Vials

Endo: About As Bad As It Gets

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Endo International plc Announces Launch of Ready-to-Use VASOSTRICT® (vasopressin injection, USP) in Pre-Mix Bottles

Endo Announces Publication of New AVEED® (testosterone undecanoate) Data in Peer-Reviewed Journal of Clinical Pharmacology; Data Evaluates Dosing Flexibility in Men With Hypogonadism

Price target decreased to US$6.17

Endo: FDA Approves Generic Form Of Vasostrict Creating Headwind Into Next Year

Investor sentiment deteriorated over the past week

Endo International plc Announces its Qwo (Collagenase Clostridium Histolyticum-Aaes) Data Presented at the American Society for Dermatologic Surgery's Annual Meeting

Third quarter 2021 earnings released: US$0.21 loss per share (vs US$0.30 loss in 3Q 2020)

Investor sentiment improved over the past week

Endo: A Win In California But Equity Value Still A Question

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Price target decreased to US$6.57

Endo International: Loses Vasostrict Trial

Investor sentiment deteriorated over the past week

Endo International: Hires Restructuring Advisor

Consensus forecasts updated

Endo International: All About Ongoing Litigation

Second quarter 2021 earnings released: US$0.044 loss per share (vs US$0.077 profit in 2Q 2020)

Investor sentiment improved over the past week

Endo: Appellate Court Denies Request To Postpone Damages Trial Might Be End O' The Road

Investor sentiment deteriorated over the past week

Endo International: Bankruptcy Seems Like The Only Practical Option

Endo International plc(NasdaqGS:ENDP) dropped from Russell 2500 Growth Index

Endo International wins FDA approval for Micafungin new formulation

Chairman Paul Campanelli has left the company

Senior Independent Director Roger Kimmel has left the company

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS US$0.20 (vs US$0.69 in 1Q 2020)

Endo International plc Announces Asset Impairment Results for the First Quarter Ended March 31, 2021

Endo International plc 2021 Q1 - Results - Earnings Call Presentation

Chairman exercised options and sold US$1.4m worth of stock

Investor sentiment deteriorated over the past week

Independent Director recently sold US$150k worth of stock

Investor sentiment deteriorated over the past week

Price target raised to US$7.45

Full year 2020 earnings released: EPS US$1.08 (vs US$1.60 loss in FY 2019)